Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 1/2008

01-02-2008

Dietary supplements, herbs and oral anticoagulants: the nature of the evidence

Author: Ann K. Wittkowsky

Published in: Journal of Thrombosis and Thrombolysis | Issue 1/2008

Login to get access

Abstract

In the US, the use of dietary supplements, including vitamins, minerals, amino acids, and herbal products, is extensive. Nonetheless, the majority of patients report that they have little information about the risks, benefits, and adverse effects of medicines, or about their potential interactions with prescription drugs. Patients taking warfarin are at particular risk of interactions with dietary supplements, yet approximately 30% use herbal or natural product supplements on a regular basis. No current governmental regulations or voluntary programs address dietary supplement interactions with prescription drugs. Case reports represent the majority of the evidence surrounding drug interactions between warfarin and dietary supplements. Those of the highest quality include, as an assessment of causality, a modification of the recently published Drug Interaction Probability Scale. Despite positive case reports, formal drug interaction studies are often negative, suggesting that numerous patient-specific influences other than the suspected interaction alone may be responsible for a particular observation. The cranberry-juice/warfarin interaction is a recent example of such a discrepancy. Healthcare providers can play an active role in improving quantity and the quality of case reports of interactions involving warfarin and dietary supplements. A registry of anticoagulant interactions with dietary supplements has been proposed, and is currently being developed through Clotcare Online Resource (http://​www.​clotcare.​com). The goal of this registry is to obtain high quality case-based evidence of drug interactions between anticoagulants and dietary supplements, to define these interactions based on clinical and monitoring outcomes, and to analyze likelihood of causation using a modification of the Drug Interaction Probability Scale.
Literature
1.
go back to reference Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef Eisenberg DM, Davis RB, Ettner SL et al (1998) Trends in alternative medicine use in the United States, 1990–1997: results of a follow-up national survey. JAMA 280:1569–1575PubMedCrossRef
2.
go back to reference Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complimentary and alternative medicine use among adults. United States, 2002. Adv Data 343:1–19PubMed Barnes PM, Powell-Griner E, McFann K, Nahin RL (2004) Complimentary and alternative medicine use among adults. United States, 2002. Adv Data 343:1–19PubMed
3.
go back to reference Gunther S, Patterson RE, Kristal AR et al (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104:27–34PubMedCrossRef Gunther S, Patterson RE, Kristal AR et al (2004) Demographic and health-related correlates of herbal and specialty supplement use. J Am Diet Assoc 104:27–34PubMedCrossRef
4.
go back to reference Wood MJ, Stewart RL, Merry H et al (2003) Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 145:806–812PubMedCrossRef Wood MJ, Stewart RL, Merry H et al (2003) Use of complementary and alternative medical therapies in patients with cardiovascular disease. Am Heart J 145:806–812PubMedCrossRef
5.
go back to reference Chagan L, Bernstein D, Cheng JW et al (2005) Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City. BMC Complement Altern Med 5:4–13PubMedCrossRef Chagan L, Bernstein D, Cheng JW et al (2005) Use of biological based therapy in patients with cardiovascular diseases in a university-hospital in New York City. BMC Complement Altern Med 5:4–13PubMedCrossRef
6.
go back to reference Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106PubMedCrossRef Holbrook AM, Pereira JA, Labiris R et al (2005) Systematic overview of warfarin and its drug and food interactions. Arch Intern Med 165:1095–1106PubMedCrossRef
7.
go back to reference Nutescu EA, Shapiro NL, Ibrahim S, West P (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5:433–451PubMedCrossRef Nutescu EA, Shapiro NL, Ibrahim S, West P (2006) Warfarin and its interactions with foods, herbs and other dietary supplements. Expert Opin Drug Saf 5:433–451PubMedCrossRef
8.
go back to reference Wong RS, Cheng G, Chan TY (2003) Use of herbal medicinals by patients receiving warfarin. Drug Saf 26:585–588PubMedCrossRef Wong RS, Cheng G, Chan TY (2003) Use of herbal medicinals by patients receiving warfarin. Drug Saf 26:585–588PubMedCrossRef
9.
go back to reference Ramsay NA, Kenny MW, Davies G, Patel JP (2005) Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 130:777–780PubMedCrossRef Ramsay NA, Kenny MW, Davies G, Patel JP (2005) Complimentary and alternative medicine use among patients starting warfarin. Br J Haematol 130:777–780PubMedCrossRef
10.
go back to reference Smith L, Ernst E, Ewings P et al (2004) Co-ingestion of herbal medicines and warfarin. Br J Gen Practice 54:439–441 Smith L, Ernst E, Ewings P et al (2004) Co-ingestion of herbal medicines and warfarin. Br J Gen Practice 54:439–441
11.
go back to reference Zuckerman IH, Steinberger EK, Ryder P, Haines S (2002) Herbal product use among anticoagulation clinic patients. Am J Health-Syst Pharm 59:379–380PubMed Zuckerman IH, Steinberger EK, Ryder P, Haines S (2002) Herbal product use among anticoagulation clinic patients. Am J Health-Syst Pharm 59:379–380PubMed
12.
go back to reference Wittkowsky AK, Bussey HI, Walker MB, Frei CR (2007) Dietary supplement use among anticoagulation clinic patients. J Thromb Haemost 5:875–877PubMedCrossRef Wittkowsky AK, Bussey HI, Walker MB, Frei CR (2007) Dietary supplement use among anticoagulation clinic patients. J Thromb Haemost 5:875–877PubMedCrossRef
13.
go back to reference Noonan C, Noonan WP (2006) Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients. Toxicology 221:4–8PubMedCrossRef Noonan C, Noonan WP (2006) Marketing dietary supplements in the United States: a review of the requirements for new dietary ingredients. Toxicology 221:4–8PubMedCrossRef
14.
go back to reference Srinivasan VS (2006) Challenges and scientific issues in the standardization of botanicals and their preparations. United States Pharmacopeia’s dietary supplement verification program—a public health program. Life Sci 78:2039–2043PubMedCrossRef Srinivasan VS (2006) Challenges and scientific issues in the standardization of botanicals and their preparations. United States Pharmacopeia’s dietary supplement verification program—a public health program. Life Sci 78:2039–2043PubMedCrossRef
15.
go back to reference Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis and implications for dosing and labeling. Nature 81:298–304 Huang SM, Temple R, Throckmorton DC, Lesko LJ (2007) Drug interaction studies: study design, data analysis and implications for dosing and labeling. Nature 81:298–304
16.
go back to reference Aronson JK (2005) Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. J Eval Clin Pract 11:195–208PubMedCrossRef Aronson JK (2005) Unity from diversity: the evidential use of anecdotal reports of adverse drug reactions and interactions. J Eval Clin Pract 11:195–208PubMedCrossRef
17.
go back to reference Kelly WN (2003) The quality of published adverse drug event reports. Ann Pharmcotherapy 37:1774–1778CrossRef Kelly WN (2003) The quality of published adverse drug event reports. Ann Pharmcotherapy 37:1774–1778CrossRef
18.
go back to reference Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRef Naranjo CA, Busto U, Sellers EM et al (1981) A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 30:239–245PubMedCrossRef
19.
go back to reference Horn JR, Hansten PD, Chan LN (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacotherapy 41:674–680CrossRef Horn JR, Hansten PD, Chan LN (2007) Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacotherapy 41:674–680CrossRef
20.
go back to reference Suvarna R, Pimrohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327:1454PubMedCrossRef Suvarna R, Pimrohamed M, Henderson L (2003) Possible interaction between warfarin and cranberry juice. BMJ 327:1454PubMedCrossRef
22.
go back to reference Grant P (2004) Warfarin and cranberry juice. An interaction? J Heart Valv Dis 13:25–26 Grant P (2004) Warfarin and cranberry juice. An interaction? J Heart Valv Dis 13:25–26
23.
go back to reference Rindone JP, Murphy TW (2006) Warfarin-cranberry juice interaction resulting in profound hypoprothrombininemia and bleeding. Am J Ther 13:283–284PubMedCrossRef Rindone JP, Murphy TW (2006) Warfarin-cranberry juice interaction resulting in profound hypoprothrombininemia and bleeding. Am J Ther 13:283–284PubMedCrossRef
24.
go back to reference Aston JL, Lodolce AE, Shapiro NL (2006) Interaction between warfarin and cranberry juice. Pharmacotherapy 26:1314–1319PubMedCrossRef Aston JL, Lodolce AE, Shapiro NL (2006) Interaction between warfarin and cranberry juice. Pharmacotherapy 26:1314–1319PubMedCrossRef
25.
go back to reference Hodek P, Trefil P, Stiborova M (2002) Flavenoids: potent and versatile biologically active compounds interacting with cytochrome P450. Chem Biol Interact 139:1–21PubMedCrossRef Hodek P, Trefil P, Stiborova M (2002) Flavenoids: potent and versatile biologically active compounds interacting with cytochrome P450. Chem Biol Interact 139:1–21PubMedCrossRef
26.
go back to reference Committee on Safety of Medicines, Medicines and Healthcare Products Regulatory Agency (2004) Interaction between warfarin and cranberry juice: new advice. Current Problems in Pharmacovigilance 30:10 Committee on Safety of Medicines, Medicines and Healthcare Products Regulatory Agency (2004) Interaction between warfarin and cranberry juice: new advice. Current Problems in Pharmacovigilance 30:10
27.
go back to reference Greenblatt DJ, von Moltke LL, Perloff ES et al (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea and fluconazole. In vitro and clinical studies Clin Pharmacol Ther 79:125–133PubMedCrossRef Greenblatt DJ, von Moltke LL, Perloff ES et al (2006) Interaction of flurbiprofen with cranberry juice, grape juice, tea and fluconazole. In vitro and clinical studies Clin Pharmacol Ther 79:125–133PubMedCrossRef
28.
go back to reference Grenier J, Fradette C, Morelli G et al (2006) Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 79:255–262PubMedCrossRef Grenier J, Fradette C, Morelli G et al (2006) Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther 79:255–262PubMedCrossRef
29.
go back to reference Lilja JJ, Backman JT, Neuvonen PJ (2007) Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine and midazolam probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther; in press Lilja JJ, Backman JT, Neuvonen PJ (2007) Effects of daily ingestion of cranberry juice on the pharmacokinetics of warfarin, tizanidine and midazolam probes of CYP2C9, CYP1A2, and CYP3A4. Clin Pharmacol Ther; in press
30.
go back to reference Zhaoping LI, Seerman NP, Carpenter CL et al (2006) Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 106:2057–2061CrossRef Zhaoping LI, Seerman NP, Carpenter CL et al (2006) Cranberry does not affect prothrombin time in male subjects on warfarin. J Am Diet Assoc 106:2057–2061CrossRef
31.
go back to reference Foti RS, Wahlstrom JL, Wienkers LC (2007) The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 35:185–188CrossRef Foti RS, Wahlstrom JL, Wienkers LC (2007) The in vitro drug interaction potential of dietary supplements containing multiple herbal components. Drug Metab Disp 35:185–188CrossRef
32.
33.
go back to reference Tai MW, Sweet BV (2006) Nattokinase for prevention of thrombosis. Am J Health Syst Pharm 63:1121–1123PubMedCrossRef Tai MW, Sweet BV (2006) Nattokinase for prevention of thrombosis. Am J Health Syst Pharm 63:1121–1123PubMedCrossRef
34.
go back to reference Cesarone MR, Belcaro G, Nicolaides AN et al (2003) Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized controlled trial. Angiology 54:531–539PubMedCrossRef Cesarone MR, Belcaro G, Nicolaides AN et al (2003) Prevention of venous thrombosis in long-haul flights with Flite Tabs: the LONFLIT-FLITE randomized controlled trial. Angiology 54:531–539PubMedCrossRef
35.
go back to reference Bussey HI, Tapson V, Cannon RO 3rd, Nolan PE Jr et al (2005) NIH conference on dietary supplements, session V: opinions and research priorities. Thromb Res 117:155–169PubMedCrossRef Bussey HI, Tapson V, Cannon RO 3rd, Nolan PE Jr et al (2005) NIH conference on dietary supplements, session V: opinions and research priorities. Thromb Res 117:155–169PubMedCrossRef
Metadata
Title
Dietary supplements, herbs and oral anticoagulants: the nature of the evidence
Author
Ann K. Wittkowsky
Publication date
01-02-2008
Publisher
Springer US
Published in
Journal of Thrombosis and Thrombolysis / Issue 1/2008
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-007-0110-0

Other articles of this Issue 1/2008

Journal of Thrombosis and Thrombolysis 1/2008 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.